Navigation Links
ChanTest to Highlight the World's Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Ion Channel Targets, Booth 5
Date:9/8/2008

Company CEO is featured speaker: 'Ion Channel Panels for Safety Assessment

and Drug Discovery' on Tuesday, September 9th at 2:30

CLEVELAND, Sept. 8 /PRNewswire/ -- ChanTest, the preeminent provider of validated ion channel-expressing cell lines and services for drug-discovery and development applications, will exhibit its expanding line of ion channel services and cell lines in booth 5 at the Ion Channel Targets conference in San Francisco September 9 and 10. ChanTest designed its ion channel cell lines and services to help drug-discovery researchers speed the drug-development process, save time and money, and ultimately -- to help make better, safer drugs. They are also becoming valuable new tools to help rescue shelved pharmaceutical compounds. Dr. Arthur (Buzz) Brown, ChanTest's founder and CEO, will address conference attendees in a presentation entitled, "Ion Channel Panels for Safety Assessment and Drug Discovery" on Tuesday, September 9th at 2:30.

"There are 400 genes encoding ion channels in the human genome, and countless more ion channels can be assembled from this gene collection," said Dr. Brown. "Ion channels control major bodily functions, including excitation, contraction, secretion, and fluid volume. As such, they have become valuable primary targets for new drug therapies for hypertension, arrhythmia, epilepsy, diabetes, and many other diseases. But too often, drug-development researchers identify unacceptable safety risks late in the drug-development process -- during the GLP patch-clamp studies that are required for IND submission. When completed early in the drug-discovery process, ChanTest's functional ion channel screens can save considerable time, money, and other resources. We set the standard for selectivity and safety profiling of drug candidates. Unlike most service organizations, we validate our cell lines for testing at each phase of the drug-discovery process. Whether you need initial high-throughput screening of hits, high-sensitivity screens for lead identification and lead optimization, or safety testing in preparation for an IND submission -- your ChanTest results will correlate."

ChanTest scientists were the first to prove hERG as the target for adverse cardiac events linked to non-cardiac drugs: Seldane (terfenadine), Propulsid (cisapride), and Nizoral (ketoconazole), and ChanTest pioneered the development of functional, cell-based ion channel testing as a means to predict cardiac side effects produced by non-cardiac drugs. Such testing is now a standard component of regulatory submissions prior to the approval of drugs for use in humans. ChanTest is committed to innovation, and is leading the next major advance in ion channel research and services with a $10 million program to develop the world's most extensive library or catalog of ion channels. ChanTest's expert electrophysiologists fully validate the ion channels for interrogation with functional, pharmacological, and biochemical assays.

The Fourth Annual Ion Channel Targets Conference and Exhibition takes place September 9-10, 2008 at the South San Francisco Conference Center.

About ChanTest

The preeminent ion channel services company, ChanTest serves its drug discovery and development customers with GLP safety and automated screening assays using its library of ion channel-expressing cell lines - the most comprehensive in the world. Since its inception in 1998, ChanTest has tested more than 18,000 compounds for more than 250 global pharmaceutical and biotech companies -- helping them to achieve their drug safety and discovery goals. ChanTest works in partnership with customers to speed the drug-development process, save time and money, and ultimately -- to help make better, safer drugs. Because of ChanTest's seminal role in this field, along with the company's uncompromising commitment to quality, ChanTest was named "most trusted fee-for-service provider" for ion channel screening in the HTStec Ion Channel Trends Survey for two years in a row. ChanTest is based in Cleveland, Ohio. For more information, please visit http://www.chantest.com.


'/>"/>
SOURCE ChanTest
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChanTest Launches New Business to Provide Validated Ion Channel Expressing Cell Lines to the Research Community
2. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Drug Discovery Technology, Booth 839
3. ChanTest Launches Redesigned Web Site
4. ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104
5. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
6. Neuralstem Reports Second Quarter Financial Results and Highlights
7. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
8. Informed Medical Communications Highlights Opportunity in Revised PhRMA Code
9. Isis Reports Financial Results and Highlights for Second Quarter of 2008
10. Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights
11. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):